Skip to content

Genotyping of Cytomegalovirus From Patients in Israel

Cytomegalovirus Glycoprotein B Genotypes in Israeli Patients: Relationship Between CMV Genotype, Clinical and Demographic Factors

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00228202
Enrollment
100
Registered
2005-09-28
Start date
2005-09-30
Completion date
Unknown
Last updated
2006-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus Infections

Keywords

cytomegalovirus, CMV, pregnancy, amniotic fluid, bone marrow, transplantation, viral load, glycoprotein B, genotyping, PCR, real-time PCR, CMV disease, Congenital CMV infection

Brief summary

The researchers select 100 cytomegalovirus (CMV) DNA samples from patients diagnosed with CMV infection. Patients include bone marrow transplant patients, pregnant women and newborns. The researchers determine viral load by real-time polymerase chain reaction (PCR). They amplify CMV-gB sequences by PCR and type by sequencing and restriction fragment length polymorphism (RFLP). The researchers obtain clinical data from patients' records. They examine association between patients' clinical status and CMV-gB genotype and viral load.

Detailed description

The study aims at finding association between CMV viral load and viral glycoprotein B genotype and the clinical status of patients suffering from CMV infection. Bone marrow transplant patients are at increased risk of developing severe CMV disease and are routinely followed for viral load. Fetuses are also at high risk for developing severe malformations and neurological defects following maternal primary infection during pregnancy. Therefore amniotic fluid from women diagnosed with CMV infection is examined for CMV presence. Newborns having congenital defects are tested for CMV excretion. There is not yet any confirmed marker for assessment of the potential severity of the viral infection and for prognosis. Therefore we shall attempt to find association between the viral load and genotype and the clinical status. CMV DNA samples prepared at the Central Virology Laboratory from clinical specimens obtained from patients for diagnostic purposes will be coded and then subjected to viral load analysis using real-time PCR. The gB genotype will be determined by either of two methods described in the literature: (a) PCR and RFLP (b) PCR and sequencing. Relevant clinical data will be retrieved from the patients clinical records and saved as coded information to match the samples. Bone marrow transplant patients will be followed for prolonged periods covering repeated viral reactivation events. Clinical records from mothers and newborns will be matched when present. Otherwise maternal and newborn samples will be kept as is. Statistical analysis will be performed to try and find association between the clinical status of patients, the viral load and the viral genotype.

Interventions

None listed

Sponsors

Sheba Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
NATURAL_HISTORY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* CMV DNA sample from a transplant patient with CMV disease. * CMV DNA from amniotic fluid of women with CMV infection * CMV DNA from urine of newborns with congenital defects compatible with CMV.

Countries

Israel

Contacts

Primary ContactElla Mendelson, PhD
ellamen@sheba.health.gov.il972-3-530-2421
Backup ContactNaty Keller, MD/PhD
kelern@sheba.health.gov.il972-3-530-2304

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026